(1)
Vancouver, British Columbia (Newsfile Corp. - July 8, 2021) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ( iCo or the Company ) is pleased to announce that the Company has received formal conditional approval from the TSX Venture Exchange (the Exchange ) of iCo s proposed business combination (the Transaction ) with Satellos Bioscience Inc. ( Satellos ).
The Company has filed an information circular on SEDAR (the Circular ) that describes the Transaction in detail and will be mailing the Circular to shareholders on or about July 13, 2021. iCo has set August 3, 2021 as the date of the special meeting of shareholders of the Company to approve the Transaction, in accordance with the rules of the Exchange. The shareholder meeting is more fully described in the Circular.
Vancouver, British Columbia (Newsfile Corp. - May 31, 2021) - iCo Therapeutics (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or the "Company"), today reported financial results for the quarter ended March 31, 2021.
Article content
Vancouver, British Columbia–(Newsfile Corp. – May 11, 2021) – Amphotericin B Technologies, Inc (“Amp B Tech” or the “Company”), a wholly-owned subsidiary of iCo Therapeutics, Inc. (TSXV: ICO) (“iCo”), announced today that two presentations related to research on the effectiveness of the Company’s Oral Amphotericin B formulation (“iCo 019”) on the SARS-Cov-2 virus have been accepted to the 2021 CSPS/PSJ/CC-CRS Joint Symposium –
Pharmaceutical Sciences in a Pandemic World. The Symposium will be held virtually from May 31 to June 3, 2021 and is sponsored by the Canadian Society for Pharmaceutical Sciences. (https://www.cspscanada.org/symposium-events/2021-csps-symposium/)
We apologize, but this video has failed to load.
(2)
Vancouver, British Columbia (Newsfile Corp. - May 11, 2021) - Amphotericin B Technologies, Inc ( Amp B Tech or the Company ), a wholly-owned subsidiary of iCo Therapeutics, Inc. (TSXV: ICO) ( iCo ), announced today that two presentations related to research on the effectiveness of the Company s Oral Amphotericin B formulation ( iCo 019 ) on the SARS-Cov-2 virus have been accepted to the 2021 CSPS/PSJ/CC-CRS Joint Symposium -
Pharmaceutical Sciences in a Pandemic World. The Symposium will be held virtually from May 31 to June 3, 2021 and is sponsored by the Canadian Society for Pharmaceutical Sciences. (https://www.cspscanada.org/symposium-events/2021-csps-symposium/)
William Jarosz, Chief Executive Officer of iCo and Amp B Tech, noted,
(2)
Vancouver, British Columbia (Newsfile Corp. - April 29, 2021) - iCo Therapeutics ( iCo or the Company ) (TSXV: ICO) (OTC: ICOTF) today reported financial results for the year ended December 31, 2020. Amounts, unless specified otherwise, are expressed in Canadian dollars and presented under International Financial Reporting Standards ( IFRS ).
William Jarosz, CEO of iCo Therapeutics Inc., noted We were very pleased by the progress of our Oral Amp B program during the year with our compound being safe and well tolerated in Phase 1b clinical trials and potential as a therapeutic agent for novel Coronavirus. We are also excited for the new strategic directions that are open for us in this new year with Satellos, and the associated concurrent financing, previously announced.